2080-2081 / 2351
Pooled of three prospective
phase II trials with cetuximab
monotherapy or with platin (N=278)
Retrospective study of patients
who received various second-line
treatments (N=194)
Vermorken et al. Cancer 2008
5.2 - 6.1 months
3.4 – 3.6 months
FDA approval
Anti-EGFR monoclonal antibodies after platinum